Critical Therapeutics, Inc. Announces National Institutes of Health (NIH)-Sponsored Study To Investigate The Efficacy Of ZYFLO(R) In Patients With Acute Exacerbations Of COPD

LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that the National Institutes of Health (NIH) will sponsor and fund a clinical trial to evaluate whether using ZYFLO® (zileuton tablets) to treat patients admitted to the hospital with acute exacerbations of chronic obstructive pulmonary disease (COPD) will shorten their hospital stay. The clinical trial is scheduled to begin in the first quarter of 2007 and is being conducted by the COPD Clinical Research Network (CRN) in 10 U.S. centers. The trial is expected to enroll 520 patients.
MORE ON THIS TOPIC